BGES Bio Bridge Science Inc (CE)

Bio-Bridge Science, Inc.(OTCBB:BGES) a developer of vaccines with broad preventative and therapeutic applications, is pleased to announce that all the pending claims of a second patent application on the papillomavirus pseudovirus technology have been allowed by the U.S. Patent and Trademark Office. Bio-Bridge expects the second patent will be issued upon payment of the issue fee. The first U.S. patent (number 6,878,541 B2) on the papillomavirus pseudovirus technology was issued in 2005. The second patent covers broader aspects of the invention and further protects the intellectual property in the papillomavirus pseudovirus technology. Loyola University Chicago owns the patent and has exclusively licensed the technology to Bio-Bridge Science, Inc. About Bio-Bridge Science: Bio-Bridge Science (http://www.bio-bridge-science.com/) is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Bio-Bridge is developing a promising new HIV Vaccine that is expected to enter clinical trials in the near future in China. The vaccine, based on exclusive technology co-developed by CEO Dr. Liang Qiao, an associate professor at Loyola University Chicago's Strich School of Medicine, targets infection in mucosal tissues, which is a unique approach to prevent and treat HIV infection. Bio-Bridge Science's GMP facility will also be used to develop vaccines against cervical cancer and colon cancer under the same technology platform. The company plans to develop these vaccines in the United States and Japan in the future. Forward Looking Statements: This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to SEC filings for additional information. Bio-Bridge Science, Inc.(OTCBB:BGES) a developer of vaccines with broad preventative and therapeutic applications, is pleased to announce that all the pending claims of a second patent application on the papillomavirus pseudovirus technology have been allowed by the U.S. Patent and Trademark Office. Bio-Bridge expects the second patent will be issued upon payment of the issue fee. The first U.S. patent (number 6,878,541 B2) on the papillomavirus pseudovirus technology was issued in 2005. The second patent covers broader aspects of the invention and further protects the intellectual property in the papillomavirus pseudovirus technology. Loyola University Chicago owns the patent and has exclusively licensed the technology to Bio-Bridge Science, Inc. About Bio-Bridge Science: Bio-Bridge Science (http://www.bio-bridge-science.com/) is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Bio-Bridge is developing a promising new HIV Vaccine that is expected to enter clinical trials in the near future in China. The vaccine, based on exclusive technology co-developed by CEO Dr. Liang Qiao, an associate professor at Loyola University Chicago's Strich School of Medicine, targets infection in mucosal tissues, which is a unique approach to prevent and treat HIV infection. Bio-Bridge Science's GMP facility will also be used to develop vaccines against cervical cancer and colon cancer under the same technology platform. The company plans to develop these vaccines in the United States and Japan in the future. Forward Looking Statements: This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to SEC filings for additional information.